PHVS vs UNIT Comparison

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Uniti is the product of the August 2025 merger of the firm with Windstream, its former primary customer. The combined firm owns a 240,000 route-mile fiber network that serves enterprise and residential customers. Selling high-capacity fiber circuits to enterprises generates about 20% of consolidated revenue. Uniti's residential networks reach about 4.5 million households, mostly in less-populated markets in the Southeast, but only about 1.9 million of these locations have been upgraded with fiber. Legacy copper-cable networks serve the remainder. Residential services account for about a third of total revenue. Small business and wholesale services provided within this residential service territory account for about 20% of revenue.